Cardiovascular science: Opportunities for translating research into improved care

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 6-10

  Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; MICRORNA; S NITROSOTHIOL;

ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; BIOGEOCHEMICAL CYCLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CONGESTIVE CARDIOMYOPATHY; GENE THERAPY; GENE TRANSFER; GENETIC SCREENING; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; STEM CELL TRANSPLANTATION; SUDDEN DEATH;

ANIMALS; ATHEROSCLEROSIS; CALCIUM; HEART DISEASES; HUMANS; INFLAMMATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84873830397     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67541     Document Type: Review

References (68)

1. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337(19): 1360-1369.
2. Roger VL, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220.
3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5): 843-854.
4. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75(5): 855-862.
5. Krützfeldt J, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005;438(7068): 685-689.
6. Kwon C, Han Z, Olson EN, Srivastava D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci U S A. 2005;102(52): 18986-18991.
7. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest. 2013;123(1): 11-18.
8. Brigden W. Uncommon myocardial diseases. The non-coronary cardiomyopathies. Lancet. 1957; 2(7007): 1179-1184.
9. Fuster V, Gersh BJ, Giuliani ER, Tajik AK, Brandenburg RP, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47(3): 525-531.
10. Mestroni L, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J. 1999;20(2): 93-102.
11. Herman DS, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012; 366(7): 619-628.
12. McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest. 2013;123(1): 19-26.
13. Andersson J, Libby P, Hansson G. Adaptive immunity and atherosclerosis. Clin Immunol. 2010; 134(1): 33-46.
14. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β?inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4): 597-605.
15. Brigham and Women's Hospital. Cardioavscular Inflammation Reduction Trial (CIRT). NIH website. http://clinicaltrials.gov/ct2/show/NCT01594333? term=low+dose+methotrexate&rank=3. Updated June 22, 2012. Accessed November 5, 2012.
16. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest. 2013;123(1): 27-36.
17. van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest. 2013; 123(1): 37-45.
18. Belin RJ, et al. Augmented protein kinase C-?- induced myofilament protein phosphorylation contributed to myofilament dysfunction in experimental congestive heart failure. Circ Res. 2007; 101(2): 195-204.
19. Liu Q, et al. Protein kinase C but not PKCβ or PKC-?, regulates contractility and heart failure susceptibility:implications of ruboxistaurin as a novel therapeutic approach. Circ Res. 2009; 105(2): 194-200.
20. Malik FI, et al. Cardiac myosin activation: a potential therapeutic approach for systemic heart failure. Science. 2011;331(6023): 1439-1443.
21. Cleland JGF, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebocontrolled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378(9792): 676-683.
22. Amgen. Study to Evaluate the Safety and Efficacy of IV Infusion Treatment with Omecamtiv Mecarbil in Subjects with Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-HF). NIH website. http://clinicaltrials.gov/ct2/show/NCT01300013?term=NCT013000 13&rank=1. Updated October 10, 2012. Accessed November 5, 2012.
23. Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest. 2013;123(1): 46-52.
24. Gwathmey JK, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987;61(1): 70-76.
25. Bers DM. Ryanodine receptor S2808 phosphorylation in heart failure: smoking gun or red herring. Circ Res. 2012;110(6): 796-799.
26. Hajjar RJ. Potential of gene therapy as a treatment for heart failure. J Clin Invest. 2013;123(1): 53-61.
27. Wang J, Faust SM, Rabinowitz JE. The next step in gene delivery: molecular engineering of adenoassociated virus serotypes. J Mol Cell Cardiol. 2011; 50(5): 793-802.
28. Miyamoto MI, et al. Adenoviral gene transfer of SERCA2a improves left ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A. 2000;97(2): 793-798.
29. Lyon AR, et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol. 2011;4(3): 362-373.
30. Mariani JA, Smolic A, Preovolos A, Byrne MJ, Power JM, Jaye DM. Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail. 2011;13(3): 247-253.
31. Jessup M, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+- ATPase in patients with advanced heart failure. Circulation. 2011;124(3): 304-313.
32. Karsner HT, Saphir O, Rodd TW. The state of the cardiac muscle in hypertrophy and atrophy. Am J Pathol. 1925;1(4): 351-371.
33. Linzbach AJ. Heart failure from the point of view of quantitative anatomy. Am J Cardiol. 1960;5: 370-382.
34. Beltrami AP, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344(23): 1750-1757.
35. Kajstura J, Leri A, Finato N, DiLoreto C, Beltrami CA, Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci U S A. 1998;95(15): 8801-8805.
36. Olivetti G, et al. Apoptosis in the failing human heart. N Engl J Med. 1997;336(16): 1131-1141.
37. Bergmann O, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923): 98-102.
38. Bearzi C, et al. Human cardiac stem cells. Proc Natl Acad Sci U S A. 2007;104(35): 14068-14073.
39. Anversa P, Kajstura J, Rota M, Leri A. Regenerating new heart with stem cells. J Clin Invest. 2013;123(1): 62-70.
40. Degenhardt K, Singh MK, Epstein JA. New approaches under development: cardiovascular embryology applied to heart disease. J Clin Invest. 2013;123(1): 71-74.
41. Epstein JA. Cardiac development and implications for heart disease. N Engl J Med. 2010; 363(17): 1638-1647.
42. Singh MK, Epstein JA. Epicardium-derived cardiac mesenchymal stem cells expanding the outer limit of heart repair. Circ Res. 2012;110(7): 904-906.
43. Smart N, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474(7353): 640-644.
44. Porrello ER, et al. Transient regenerative potential of the neonatal mouse heart. Science. 2011; 331(6020): 1078-1080.
45. George AL Jr. Molecular and genetic basis of sudden cardiac death. J Clin Invest. 2013;123(1): 75-83.
46. Cerrone M, Napolitano C, Priori SG. Genetics of ion-channel disorders. Curr Opin Cardiol. 2012;27(3): 242-252.
47. Ackerman MJ, et al. HRS/EHRA Expert Consensus Statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8(8): 1308-1339.
48. Priori SG, Napolitano C, Di Pasquale E, Condorelli G. Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin Invest. 2013;123(1): 84-91.
49. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4): 663-676.
50. Davis RP, van den Berg CW, Casini S, Braam SR, Mummery CL. Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development. Trends Mol Med. 2011; 17(9): 475-484.
51. Itzhaki I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011; 471(7337): 225-229.
52. Yazawa M, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature. 2011;471(7337): 230-234.
53. Obraztov VP, Strazhesko ND. Simtomatiologii I diagnostike tromboza venecchinikh arterial cerdtsa. In: Vorobeva VA, Konchalovski MP, eds. Trudi Pervogo Sesda Rossushkikh Terapevtov. Vol 10. Moscow, Russia: Tovareschejestvo Tepografe, A.E. Mamontov; 1910: 26-43 (Russian).
54. Braunwald E. The treatment of acute myocardial infarction: the past, the present, and the future. Eur Heart J Acute Cardiovasc Care. 2012;1(1): 9-12.
55. Julian DG. Treatment of cardiac arrest in acute myocardial ischemia and infarction. Lancet. 1961; 2(7207): 840-844.
56. Maroko PR, et al. Factors influencing infarct size following experimental coronary artery occlusion. Circulation. 1971;43(1): 67-82.
57. Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI. Intracoronary administration of fibrinolysin in acute myocardial infarction. Ter Arkh. 1976;48(4): 8-19.
58. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985; 76(5): 1713-1719.
59. Hausenloy DJ, Yellon DM. Myocardial ischemiareperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1): 92-100.
60. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5): 1124-1136.
61. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic "preconditioning" protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993; 87(3): 893-899.
62. Zhao ZQ, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285(2):H579-H588.
63. Braunwald E. Clinical efforts to reduce myocardial infarct size - the next step. J Cardiovasc Pharm Ther. 2011;16(3-4): 349-353.
64. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288(5789): 373-376.
65. Koshland DE Jr. The molecule of the year. Science. 1992;258(5090):1861.
66. Stamler JS, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A. 1992;89(1): 444-448.
67. McMahon TJ, et al. A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension. Proc Natl Acad Sci U S A. 2005;102(41): 14801-14806.
68. Haldar SM, Stamler JS. S-nitrosylation: integrator of cardiovascular performance and oxygen delivery. J Clin Invest. 2013;123(1): 101-110.